Form 4: Protagonist Therapeutics Director Exercises Stock Options

Protagonist Therapeutics Director Harold E. Selick exercised stock options, acquiring 14,299 shares of common stock.

Summary

• Harold E. Selick, a Director of Protagonist Therapeutics, Inc. (PTGX), reported a transaction on January 9, 2026.
• The transaction involved the exercise of stock options to acquire 14,299 shares of common stock.
• The exercise price for these shares was $4.21 per share.
• Following this transaction, Harold E. Selick directly beneficially owns 60,845 shares of Protagonist Therapeutics Common Stock.
• The stock options exercised were fully vested and had an expiration date of April 29, 2026.
• After the exercise, no derivative securities (stock options) are beneficially owned by the reporting person.

Sentiment

Score: 7

Explanation: The exercise of stock options by a director, leading to an increase in their direct beneficial ownership, is generally viewed as a positive signal of confidence in the company's future performance.

Positives

• A Director increasing their direct ownership in the company by exercising stock options can signal confidence in the company's future prospects.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction (exercise of stock options) and does not provide specific industry context or relate to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: The transaction slightly increases the number of outstanding shares, but the impact on overall share float is minimal. It also signals a director's continued investment in the company.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Harold E. Selick, Insider Transaction, Stock Options, Common Stock, SEC Form 4, Director Ownership